In addition to suppressing tumor progression, hUCMSCs promote granulocytic differentiation of immature myeloid cancer cells in acute promyelocytic leukemia (APL), which drives the disease into remission by activating MEK/ERK pathways [194]. Here, MAP2K7 is linked to acute promyelocytic leukemia.